What question did this study set out to answer?

This analysis aims to identify factors that predict early discontinuation of adjuvant palbociclib in early-stage HR+/HER2- breast cancer patients.

Abstract PS3-07-14: Predictors of early discontinuation of adjuvant palbociclib in early HR+/ HER2- breast cancer: final analysis of the PALLAS trial integrating patient-reported outcomes

View Full Paper

Ask AI

Bookmark

This analysis aims to identify factors that predict early discontinuation of adjuvant palbociclib in early-stage HR+/HER2- breast cancer patients.
Analyzed data from the PALLAS trial's safety population of 5736 patients.
Used cumulative incidence curves and cause-specific hazard models to assess discontinuation risks.
Evaluated associations with clinical, demographic factors, toxicities, and patient-reported outcomes.
41.3% of patients discontinued palbociclib early, mainly not due to disease progression or death.
Median time to discontinuation was 7.7 months; 9.2% discontinued very early (≤3 months).
Key predictors of early discontinuation included age, nodal stage, low quality of life, and financial difficulties.

No takes yet. Share an insight, caveat, or question.

Analysis identifies factors influencing early discontinuation of palbociclib in early breast cancer, suggesting patient-reported outcomes are vital.

Vetter et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis identifies factors influencing early discontinuation of palbociclib in early breast cancer, suggesting patient-reported outcomes are vital.